Literature DB >> 20842338

[The future of depression research].

F Holsboer1.   

Abstract

As in the past, future depression research will be oriented to the genetics and pharmacology of antidepressants as well as molecular and clinical biomarkers. Using new technologies patient populations with practically equal disease mechanisms will be identified which can be specifically treated with new drugs or a combination of presently available drugs. This signifies the integration of neuroscientific knowledge into the diagnostics of depression. The application of a personalized depression therapy supported by genetic testing and biomarkers raises the possibility of early recognition of the risk of disease and a targeted intervention before the symptoms of disease emerge.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842338     DOI: 10.1007/s00115-010-3053-1

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  31 in total

Review 1.  The corticosteroid receptor hypothesis of depression.

Authors:  F Holsboer
Journal:  Neuropsychopharmacology       Date:  2000-11       Impact factor: 7.853

2.  A clinical analysis of the effects of tofranil in depression. Longitudinal and follow-up studies. Treatment of blood-relations.

Authors:  J ANGST
Journal:  Psychopharmacologia       Date:  1961-12-19

Review 3.  Sequencing technologies - the next generation.

Authors:  Michael L Metzker
Journal:  Nat Rev Genet       Date:  2009-12-08       Impact factor: 53.242

4.  Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder.

Authors:  H J Williams; N Norton; S Dwyer; V Moskvina; I Nikolov; L Carroll; L Georgieva; N M Williams; D W Morris; E M Quinn; I Giegling; M Ikeda; J Wood; T Lencz; C Hultman; P Lichtenstein; D Thiselton; B S Maher; A K Malhotra; B Riley; K S Kendler; M Gill; P Sullivan; P Sklar; S Purcell; V L Nimgaonkar; G Kirov; P Holmans; A Corvin; D Rujescu; N Craddock; M J Owen; M C O'Donovan
Journal:  Mol Psychiatry       Date:  2010-04-06       Impact factor: 15.992

5.  P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder.

Authors:  Susanne Lucae; Daria Salyakina; Nicholas Barden; Mario Harvey; Bernard Gagné; Michel Labbé; Elisabeth B Binder; Manfred Uhr; Marcelo Paez-Pereda; Inge Sillaber; Marcus Ising; Tanja Brückl; Roselind Lieb; Florian Holsboer; Bertram Müller-Myhsok
Journal:  Hum Mol Genet       Date:  2006-07-05       Impact factor: 6.150

6.  Putative biological mechanisms for the association between early life adversity and the subsequent development of PTSD.

Authors:  Rachel Yehuda; Janine D Flory; Laura C Pratchett; Joseph Buxbaum; Marcus Ising; Florian Holsboer
Journal:  Psychopharmacology (Berl)       Date:  2010-08-13       Impact factor: 4.530

7.  Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder.

Authors:  Nicholas Barden; Mario Harvey; Bernard Gagné; Eric Shink; Monique Tremblay; Catherine Raymond; Michel Labbé; André Villeneuve; Denis Rochette; Lise Bordeleau; Herbert Stadler; Florian Holsboer; Bertram Müller-Myhsok
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-06-05       Impact factor: 3.568

8.  The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders.

Authors:  I Heuser; A Yassouridis; F Holsboer
Journal:  J Psychiatr Res       Date:  1994 Jul-Aug       Impact factor: 4.791

9.  A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.

Authors:  Brendon Binneman; Douglas Feltner; Sheela Kolluri; Yuanjun Shi; Ruolun Qiu; Thomas Stiger
Journal:  Am J Psychiatry       Date:  2008-04-15       Impact factor: 18.112

10.  Meta-analysis of genome-wide association data identifies a risk locus for major mood disorders on 3p21.1.

Authors:  Francis J McMahon; Nirmala Akula; Thomas G Schulze; Pierandrea Muglia; Federica Tozzi; Sevilla D Detera-Wadleigh; C J M Steele; René Breuer; Jana Strohmaier; Jens R Wendland; Manuel Mattheisen; Thomas W Mühleisen; Wolfgang Maier; Markus M Nöthen; Sven Cichon; Anne Farmer; John B Vincent; Florian Holsboer; Martin Preisig; Marcella Rietschel
Journal:  Nat Genet       Date:  2010-01-17       Impact factor: 38.330

View more
  8 in total

1.  [A new evidence and consensus-based German guidelines for diagnosis and treatment of bipolar disorders].

Authors:  M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

2.  [Biologism controversy: ethical implications for psychiatry].

Authors:  M Stier; S Muders; M Rüther; B Schöne-Seifert
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 3.  [Between psyche and brain : State of the art in psychiatry].

Authors:  T Fuchs
Journal:  Nervenarzt       Date:  2017-05       Impact factor: 1.214

Review 4.  [The development of depression: the role of brain-derived neurotrophic factor].

Authors:  H Stuke; R Hellweg; F Bermpohl
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

Review 5.  Normative preconditions for the assessment of mental disorder.

Authors:  Marco Stier
Journal:  Front Psychol       Date:  2013-09-09

6.  The biopsychosocial model between biologism and arbitrariness. A Commentary to H. Helmchen.

Authors:  Marco Stier
Journal:  Front Psychol       Date:  2014-02-19

7.  How to Include Patients' Perspectives in the Study of the Mind: A Review of Studies on Depression.

Authors:  Henriette Löffler-Stastka; Kathrin Bednar; Ingrid Pleschberger; Tamara Prevendar; Giada Pietrabissa
Journal:  Front Psychol       Date:  2021-04-12

8.  Redesigning antidepressant drug discovery.

Authors:  Florian Holsboer
Journal:  Dialogues Clin Neurosci       Date:  2014-03       Impact factor: 5.986

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.